Pulse Biosciences Inc (PLSE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Pulse Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 35.10 $ — 98% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -20.6% failed
- More than 10% revenue growth is expected for the coming year 236.7% passed
- Share count grows by less than 3% a year 25.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion -360.0% failed
- Goodwill from acquisitions does not grow faster than revenue 2.9% failed
- Net debt below twice EBITDA 73 m net cash passed
- Operating cash flow covers the profits of the last three years 45 m failed
- Return on capital at 15% or higher, or up versus two years ago -87.2% failed
- Insiders hold at least 10% or are net buyers 73.4% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7.9% below the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.07 | -1.23 – -0.91 | 3 | -41.8% | 2 |
| 12/31/2027 | -1.09 | -1.30 – -0.88 | 9 | -1.9% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.31 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 2 | -4.40 | -1,165.00 | -9 | -9 |
| 2025: Q1 | -0.25 | – | 1 | – | -2,018.60 | -14 | -14 |
| 2025: Q2 | -0.28 | – | 0 | – | – | -13 | -13 |
| 2025: Q3 | -0.29 | – | 0 | – | -22,540.70 | -13 | -13 |
| 2025: Q4 | -0.26 | – | 0 | -84.10 | -6,603.40 | -15 | -15 |
| 2026: Q1 | -0.27 | – | 0 | -51.80 | -4,633.70 | -15 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -10 | -10 | -0.86 | -8 | 25 | 26 |
| 2017 | 0 | -26 | -26 | -1.73 | -11 | 46 | 50 |
| 2018 | 0 | -38 | -38 | -2.20 | -24 | 66 | 71 |
| 2019 | 0 | -48 | -46 | -2.22 | -34 | 31 | 42 |
| 2020 | 0 | -50 | -50 | -2.14 | -35 | 23 | 41 |
| 2021 | 1 | -63 | -63 | -2.26 | -54 | 36 | 54 |
| 2022 | 1 | -58 | -59 | -1.74 | -47 | -2 | 78 |
| 2023 | 0 | -44 | -42 | -0.88 | -33 | 44 | 59 |
| 2024 | 0 | -56 | -54 | -0.92 | -36 | 115 | 132 |
| 2025 | 0 | -77 | -73 | -1.08 | -54 | 81 | 96 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Pulse Biosciences, Inc. ist ein neuartiges bioelektrisches Medizinunternehmen.
| Employees | 116 |
|---|---|
| Headquarters | Miami, FL |
| Address | 601 Brickell Key Drive, 33131 Miami, United States |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
| IPO Date | 18. May 2016 |
| ISIN | US74587B1017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Paul Arthur LaViolette M.B.A. | President, CEO & Co-Chairman of the Board | 1958 |
| Jon Skinner | Chief Financial Officer | 1986 |
| Darrin R. Uecker | CTO & Director | 1966 |
| Liane Teplitsky | Chief Operating Officer | 1977 |
| Steven T. Weber | VP of Accounting, Principal Accounting Officer & Global Corporate Controller | 1976 |
| Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary | 1969 |
| Patty Perla | Vice President of Human Resources | – |
| David Danitz | Senior Vice President of Engineering | – |
| Gansevoort Dunnington M.D. | Chief Medical Officer | – |
| Niv Ad M.D. | Chief Science Officer of Cardiac Surgery | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.